Collagenase Clostridium Histolyticum (Xiaflex)


Indications for Prior Authorization:

  • Dupuytren's contracture (hand) in Adults
  • Peyronie's Disease

Patients must meet the following criteria for the indications above:

  • Patient must have a palpable cord

Dupuytren's Contracture

  • Diagnosis of Dupuytren's Contracture AND
  • Have at least one finger (not thumb) flexion contracture with a palpable cord of 20 to 100 degrees in the metatarsophalangeal joint (MP) or a proximal interphalageal (PIP) joint

Peyronie's Disease

  • Diagnosis of Peyronie's disease diagnosed by a urologist (prescriber need not be urologist)

The drug is not approved for any use not mentioned above:

  • Any condition not listed above as an approved condition


  • Xiaflex must be administered by a healthcare provider experienced in injection procedures of the hand

Dupuytren's Contracture

  • The dose of Xiaflex is 0.58 mg per injection into a palpable cord with a contracture of a metacarpophalangeal (MP) joint or a proximal interphalangeal (PIP) joint
  • Approximately 24 hours after injection, perform a finger extension procedure to facilitate cord disruption
  • Four weeks after the initial injection and finger extension, if a MP or PIP contracture remains, the cord may be re-injected with a single dose of 0.58 mg. Repeat finger extension in 24 hours
  • Injections and finger extension procedures may be administered up to 3 times per cord at approximately 4-week intervals

Peyronie’s Disease

  • Up to 2 injections of 0.58 mg injected into target plaque, administered 1 to 3 days apart
  • For each plaque causing the curvature deformity, up to four treatment cycles may be administered
  • Each treatment cycle consists of two injections given at six-week intervals for up to four cycles (maximum of 8 injections per plaque for the entire treatment course)


  • Initial approval to assess patient’s response
  • Renew for 2 more injections if contracture persists
  • Maximum treatment 3 injections per cord


Last review date: July 20, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar